Michelle Carr – BioTuesdays

Developments

Neuronetics Q4 preliminary revenue tops guidance

Neuronetics (NASDAQ:STIM) reported preliminary unaudited revenue for the fourth quarter of 2020 between $15-million and $15.5-million, compared with previous guidance of $13-million and $13.5-million. “During the...

January 13, 2021

Executive Moves

Fibrocor Therapeutics names biotech veteran Joseph Walewicz as CFO

Closely-held Fibrocor Therapeutics appointed Joseph Walewicz, a biotech veteran with more than 25 years of experience in finance, capital markets and business development, as CFO. Prior to joining Fibrocor, Mr. Walewicz...

January 7, 2021

Developments

Hepion Pharma posts positive Phase 2a low dose data for CRV431 in advanced NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive top line data from the low dose cohort in its Phase 2a AMBITION clinical trial of 75 mg CRV431, an oral, once-daily novel cyclophilin inhibitor, for the treatment...

December 30, 2020

Developments

Soricimed to investigate SOR-C13 to treat COVID-19

Closely-held Soricimed Biopharma, benefiting from funding support from the National Research Council of Canada Industrial Research Assistance Program, will investigate the potential therapeutic role its cancer drug...

December 17, 2020

Developments

First patients enrolled in Eyenovia Phase 3 MicroLine study for presbyopia

Eyenovia (NASDAQ:EYEN) announced that the first set of patients has been enrolled in the company’s Phase 3 VISION-1 study of MicroLine, a proprietary pilocarpine formulation delivered via its Optejet dispenser for the...

December 16, 2020

Markets

Analysts start SQZ Biotechnologies at buy

Analysts with Stifel and BTIG launched coverage of SQZ Biotechnologies (NYSE:SQZ) with “buy” ratings and price targets of $38 and $40, respectively. The stock closed at $27.62 on Nov. 23. “We believe SQZ’s Cell Squeeze...

November 24, 2020

Markets

Ladenburg starts Tarsus Pharma at buy; PT $42

Ladenburg Thalmann initiated coverage of Tarsus Pharmaceuticals (NASDAQ:TARS) with a “buy” rating and $42 price target. The stock closed at $23.19 on Nov. 19. Tarsus focuses on the development of novel treatments for...

November 10, 2020

Markets

SVB Leerink cuts Neovasc PT to $2 from $6

SVB Leerink slashed its price target for Neovasc (NASDAQ:NVCN) to $2 from $6, citing timing uncertainty for a U.S. launch of the company’s Reducer stent for percutaneous treatment of refractory angina. The stock closed...

November 6, 2020

Developments

Aurinia voclosporin ophthalmic solution fails Phase 2/3 dry eye trial

The Phase 2/3 AUDREY clinical study evaluating Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome did not achieve statistical...

November 2, 2020

Markets

AGP starts MediPharm Labs at buy; PT $2 (Canadian)

Alliance Global Partners initiated coverage of MediPharm Labs (TSX:LABS) with a “buy” rating and price target of $2 (Canadian). The stock was quote at 82 cents around midday on Nov. 2. “We see MediPharm in a position to...

November 2, 2020

Author - Michelle Carr

Neuronetics Q4 preliminary revenue tops guidance

Fibrocor Therapeutics names biotech veteran Joseph Walewicz as CFO

Hepion Pharma posts positive Phase 2a low dose data for CRV431 in advanced NASH

Soricimed to investigate SOR-C13 to treat COVID-19

First patients enrolled in Eyenovia Phase 3 MicroLine study for presbyopia

Analysts start SQZ Biotechnologies at buy

Ladenburg starts Tarsus Pharma at buy; PT $42

SVB Leerink cuts Neovasc PT to $2 from $6

Aurinia voclosporin ophthalmic solution fails Phase 2/3 dry eye trial

AGP starts MediPharm Labs at buy; PT $2 (Canadian)

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter